Aardvark Therapeutics, Inc.
AARD
$8.49
-$0.50-5.56%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.70M | 2.72M | 1.39M | 1.03M | 2.04M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 15.85M | 10.47M | 9.45M | 5.09M | 6.07M |
Operating Income | -15.85M | -10.47M | -9.45M | -5.09M | -6.07M |
Income Before Tax | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -14.37M | -9.31M | -8.78M | -4.18M | -5.45M |
EBIT | -15.85M | -10.47M | -9.45M | -5.09M | -6.07M |
EBITDA | -15.84M | -10.47M | -9.44M | -5.09M | -6.07M |
EPS Basic | -0.66 | -0.71 | -2.16 | -1.05 | -1.37 |
Normalized Basic EPS | -0.41 | -0.44 | -1.34 | -0.64 | -0.86 |
EPS Diluted | -0.66 | -0.71 | -2.16 | -1.05 | -1.37 |
Normalized Diluted EPS | -0.41 | -0.44 | -1.34 | -0.64 | -0.86 |
Average Basic Shares Outstanding | 21.69M | 13.19M | 4.06M | 3.99M | 3.97M |
Average Diluted Shares Outstanding | 21.69M | 13.19M | 4.06M | 3.99M | 3.97M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |